There are currently 410 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755
Recruiting
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Exelixis Clinical Site #1, Grand Rapids, Michigan
Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Register for Updates
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
NCT06413680
Recruiting
This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Start Midwest Cancer Research, Grand Rapids, Michigan
Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Register for Updates
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
NCT06564974
Recruiting
The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.
Gender:
MALE
Ages:
2 years and above
Trial Updated:
06/18/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Duchenne Muscular Dystrophy
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Local Institution - 149, Grand Rapids, Michigan
Conditions: Schizophrenia
Register for Updates
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167
Recruiting
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Malignancies, Hematologic Malignancies
Register for Updates
Sleep for Stroke Management and Recovery Trial
NCT03812653
Recruiting
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Trinity Health Saint Mary's, Grand Rapids, Michigan
Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Register for Updates
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
NCT06264180
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Advanced Melanoma
Register for Updates
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124
Recruiting
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: South Texas Accelerated Research Therapeutics, LLC Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumors
Register for Updates
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
06/16/2025
Locations: Research Site, Grand Rapids, Michigan
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
06/13/2025
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan
Conditions: Muscular Atrophy, Spinal
Register for Updates
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013
Recruiting
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Cancer
Register for Updates
Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction
NCT05986890
Recruiting
This study is intended to investigate whether roux-en-y bypass surgery is superior to conventional loop gastrojejunostomy for Malignant gastric outlet obstruction in terms of tolerance to solid food intake. We hypothesize that roux-en-y bypass will be associated with improved solid food intake in the first 30 days after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: G. Paul Wright, Grand Rapids, Michigan
Conditions: Malignant Gastric Outlet Obstruction
Register for Updates